Genaro Escobar Cruz

Cutaneous oncology has entered a new phase defined by the integration of early detection strategies, molecular risk stratification, and biologically guided systemic therapies. Melanoma, although less frequent than keratinocyte cancers, remains the most lethal form of skin cancer, while basal cell carcinoma and Merkel-cell carcinoma contribute significantly to global oncologic burden. This review analyzes the contemporary transformation of cutaneous oncology within the precision medicine framework, focusing on three core domains: stage-based prognosis, genomic characterization, and targeted and immune-based therapeutic interventions. Evidence from landmark clinical trials demonstrates that BRAF-mutated melanoma benefits from combined BRAF/MEK inhibition, while immune checkpoint blockade—particularly PD-1–based regimens—achieves durable survival in advanced disease. Long-term survival data confirm sustained benefit in a subset of patients, redefining expectations for metastatic melanoma outcomes. In addition, immunotherapy has shown meaningful activity in other aggressive cutaneous malignancies such as Merkel-cell carcinoma. The integration of staging systems, molecular diagnostics, and systemic therapies illustrates a dual therapeutic paradigm in which tumor genotype and immune context guide treatment selection. From an international perspective, including healthcare systems in Mexico, Colombia, and Ecuador, the implementation of precision oncology requires structured integration of early detection, standardized pathology, essential genomic testing, and multidisciplinary therapeutic access. Cutaneous oncology in the precision era is therefore characterized by coordinated biological insight and clinical application, forming the basis for advanced academic instruction and evidence-based oncologic practice.

Complex multimorbidity has become a defining feature of contemporary internal medicine, particularly within inflammatory–metabolic intersections such as dermatologic and endocrine disorders. As chronic conditions cluster in structured cardiometabolic networks, traditional disease-specific guideline approaches increasingly generate therapeutic conflict, polypharmacy, and reduced predictive accuracy in high-complexity patients. This study developed and evaluated an integrated precision decision-making framework designed to reconcile inflammatory burden, endocrine dysregulation, cardiovascular risk stratification, medication safety, and patient-centered prioritization within a unified clinical model. Multidimensional analysis demonstrated coherent cardiometabolic clustering with measurable inflammatory–metabolic overlap. As multimorbidity complexity increased, medication burden, adverse drug event risk, and guideline conflict rose progressively under traditional management approaches, while predictive discrimination declined. In contrast, the integrated precision framework showed lower conflict indices and improved predictive performance across escalating strata of complexity. Outcome prioritization analysis revealed a structured distribution balancing cardiovascular stabilization, metabolic control, inflammatory skin management, polypharmacy reduction, and quality-of-life considerations. These findings support the transition from fragmented, disease-centered optimization toward an integrated, value-based, and precision-guided model of internal medicine capable of addressing the biological and therapeutic interdependence characteristic of complex chronic disease networks.

Immunologic and inflammatory skin disorders have undergone a profound conceptual transformation over the past two decades. Conditions such as psoriasis, atopic dermatitis, autoimmune blistering diseases, and cutaneous lupus erythematosus are now understood as immune-mediated entities driven by specific pathogenic pathways rather than solely morphologic diagnoses. This review synthesizes contemporary high-impact literature to analyze emerging diagnostic and therapeutic paradigms, emphasizing the transition from broad immunosuppression to mechanism-informed precision targeting. Particular attention is given to the IL-23/Th17 axis in psoriasis, type 2 inflammation in atopic dermatitis, and autoantibody-mediated mechanisms in blistering disorders. The review further compares cytokine-specific biologics with intracellular pathway modulators such as JAK inhibitors, highlighting distinctions in monitoring requirements, breadth of immunologic impact, and practical considerations. A structured therapeutic sequencing model is proposed, integrating clinical severity, immunologic alignment, safety monitoring, and healthcare feasibility. Special consideration is given to implementation in diverse international contexts, including Mexico, Colombia, and Ecuador. The findings support a unified framework in which diagnosis remains clinically grounded but conceptually reinforced by immunopathogenesis, and treatment selection is increasingly guided by targeted immune modulation. This paradigm reflects the broader evolution of translational medicine and underscores the necessity of adaptable, evidence-based strategies in inflammatory dermatology.

Tumor adaptation and therapeutic resistance remain central challenges in modern oncology despite significant advances in targeted therapy and immunotherapy. Contemporary evidence indicates that resistance is not an isolated pharmacologic failure but an emergent property of evolving tumor ecosystems characterized by intratumoral heterogeneity, clonal selection, immune modulation, and tumor microenvironmental support. This review synthesizes landmark mechanistic and translational studies to construct an integrated framework linking evolutionary dynamics, signaling plasticity, immune escape, and precision oncology implementation. Across targeted therapies, resistance frequently develops through pathway reactivation, bypass signaling, and adaptive rewiring under selective pressure. In immunotherapy, resistance involves immune editing, checkpoint regulation complexity, impaired antigen presentation, and stromal-mediated immune exclusion. The tumor microenvironment further stabilizes therapy-tolerant populations through niche protection and cytokine-driven suppression. Genome-driven oncology provides a translational pathway for personalization; however, effective precision strategies must be dynamic and iterative, accounting for tumor evolution rather than relying on static baseline profiling. This integrative perspective supports improved therapeutic reasoning, multidisciplinary decision-making, and context-adapted implementation in diverse healthcare systems, including emerging oncology infrastructures in Latin America. Understanding resistance as an evolutionary and ecological phenomenon strengthens both clinical strategy design and advanced oncology education.